Literature DB >> 23061077

The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada.

M Reza Maleki-Yazdi1, Suzanne M Kelly, S Ys Lam, Mihaela Marin, Martin Barbeau, Valery Walker.   

Abstract

INTRODUCTION: No recent Canadian studies with physician- and spirometry-confirmed diagnosis of chronic obstructive pulmonary disease (COPD) that assessed the burden of COPD have been published.
OBJECTIVE: To assess the costs associated with maintenance therapy and treatment for acute exacerbations of COPD (AECOPD) over a one-year period.
METHODS: Respirologists, internists and family practitioners from across Canada enrolled patients with an established diagnosis of moderate to severe COPD (Global initiative for chonic Obstructive Lung Disease stages 2 and 3) confirmed by postbronchodilator spirometry. Patient information and health care resources related to COPD maintenance and physician-documented AECOPD over the previous year were obtained by chart review and patient survey.
RESULTS: A total of 285 patients (59.3% male; mean age 70.4 years; mean pack years smoked 45.6; mean duration of COPD 8.2 years; mean postbronchodilator forced expiratory volume in 1 s 58.0% predicted) were enrolled at 23 sites across Canada. The average annual COPD-related cost per patient was $4,147. Across all 285 patients, maintenance costs were $2,475 per patient, of which medications accounted for 71%. AECOPD treatment costs were $1,673 per patient, of which hospitalizations accounted for 82%. Ninety-eight patients (34%) experienced a total of 157 AECOPD. Treatment of these AECOPD included medications and outpatient care, 19 emergency room visits and 40 hospitalizations (mean length of stay 8.9 days). The mean cost per AECOPD was $3,036. DISCUSSION: The current costs associated with moderate and severe COPD are considerable and will increase in the future. Appropriate use of medications and strategies to prevent hospitalizations for AECOPD may reduce COPD-related costs because these were the major cost drivers.

Entities:  

Mesh:

Year:  2012        PMID: 23061077      PMCID: PMC3473007          DOI: 10.1155/2012/328460

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  14 in total

1.  Barriers to the use of spirometry in general practice.

Authors:  Julia A E Walters; Emily Hansen; Peter Mudge; David P Johns; E Haydn Walters; Richard Wood-Baker
Journal:  Aust Fam Physician       Date:  2005-03

2.  Costs of COPD in Sweden according to disease severity.

Authors:  Sven-Arne Jansson; Fredrik Andersson; Sixten Borg; Asa Ericsson; Elsy Jönsson; Bo Lundbäck
Journal:  Chest       Date:  2002-12       Impact factor: 9.410

3.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

Authors:  J J Soler-Cataluña; M A Martínez-García; P Román Sánchez; E Salcedo; M Navarro; R Ochando
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

4.  Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study.

Authors:  Andrea S Gershon; Laura Warner; Paul Cascagnette; J Charles Victor; Teresa To
Journal:  Lancet       Date:  2011-09-10       Impact factor: 79.321

5.  Underuse of spirometry by general practitioners for the diagnosis of COPD in Italy.

Authors:  G Caramori; G Bettoncelli; R Tosatto; F Arpinelli; G Visonà; G Invernizzi; B F Novelletto; A Papi; I M Adcock; A Ciaccia
Journal:  Monaldi Arch Chest Dis       Date:  2005-03

6.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care.

Authors:  Denis E O'Donnell; Paul Hernandez; Alan Kaplan; Shawn Aaron; Jean Bourbeau; Darcy Marciniuk; Meyer Balter; Gordon Ford; Andre Gervais; Yves Lacasse; Francois Maltais; Jeremy Road; Graeme Rocker; Don Sin; Tasmin Sinuff; Nha Voduc
Journal:  Can Respir J       Date:  2008 Jan-Feb       Impact factor: 2.409

7.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

8.  Early detection and impaired quality of life in COPD GOLD stage 0: a pilot study.

Authors:  M Reza Maleki-Yazdi; Christine K Lewczuk; Jennifer M Haddon; Nozhat Choudry; Nancy Ryan
Journal:  COPD       Date:  2007-12       Impact factor: 2.409

Review 9.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

Authors:  Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski
Journal:  Am J Respir Crit Care Med       Date:  2007-05-16       Impact factor: 21.405

10.  The cost of moderate and severe COPD exacerbations to the Canadian healthcare system.

Authors:  N Mittmann; L Kuramoto; S J Seung; J M Haddon; C Bradley-Kennedy; J M Fitzgerald
Journal:  Respir Med       Date:  2007-12-20       Impact factor: 3.415

View more
  12 in total

Review 1.  Burden of chronic obstructive pulmonary disease: healthcare costs and beyond.

Authors:  Sara M May; James T C Li
Journal:  Allergy Asthma Proc       Date:  2015 Jan-Feb       Impact factor: 2.587

2.  Implementation of a targeted screening program to detect airflow obstruction suggestive of chronic obstructive pulmonary disease within a presurgical screening clinic.

Authors:  Chantal Robitaille; Esther Dajczman; Andrew M Hirsch; David Small; Pierre Ernst; Dana Porubska; Mark Palayew
Journal:  Can Respir J       Date:  2015-05-11       Impact factor: 2.409

3.  Influence of comorbidities in long-term survival of chronic obstructive pulmonary disease patients.

Authors:  Selma Aydogan Eroglu; Hakan Gunen; Halil Ibrahim Yakar; Ethem Yildiz; Murat Kavas; Dildar Duman
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

Review 4.  Insights about the economic impact of chronic obstructive pulmonary disease readmissions post implementation of the hospital readmission reduction program.

Authors:  Valerie G Press; R Tamara Konetzka; Steven R White
Journal:  Curr Opin Pulm Med       Date:  2018-03       Impact factor: 3.155

5.  Integrated interdisciplinary care for patients with chronic obstructive pulmonary disease reduces emergency department visits, admissions and costs: a quality assurance study.

Authors:  Esther Dajczman; Chantal Robitaille; Pierre Ernst; Andrew Michael Hirsch; Norman Wolkove; David Small; Judy Bianco; Hartley Stern; Mark Palayew
Journal:  Can Respir J       Date:  2013 Sep-Oct       Impact factor: 2.409

Review 6.  Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review.

Authors:  Tam Dang-Tan; Afisi Ismaila; Shiyuan Zhang; Victoria Zarotsky; Mark Bernauer
Journal:  BMC Res Notes       Date:  2015-09-21

7.  Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.

Authors:  Xuehua Ke; Jessica Marvel; Tzy-Chyi Yu; Debra Wertz; Caroline Geremakis; Liya Wang; Judith J Stephenson; David M Mannino
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-07-27

Review 8.  The association between vitamin D and COPD risk, severity, and exacerbation: an updated systematic review and meta-analysis.

Authors:  Min Zhu; Ting Wang; Chengdi Wang; Yulin Ji
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-10-19

9.  Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada.

Authors:  Jean-Eric Tarride; Robert B Hopkins; Natasha Burke; Jason R Guertin; Daria O'Reilly; Charlene D Fell; Genevieve Dion; Martin Kolb
Journal:  Clinicoecon Outcomes Res       Date:  2018-02-22

10.  Factors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record data.

Authors:  Meng Li; Fengyan Wang; Rongchang Chen; Zhenyu Liang; Yumin Zhou; Yuqiong Yang; Shengqi Chen; Carolina Oi Lam Ung; Hao Hu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.